Skip to main content
. Author manuscript; available in PMC: 2017 Dec 5.
Published in final edited form as: Nat Biomed Eng. 2017 Jun 5;1:0078. doi: 10.1038/s41551-017-0078

Figure 2. A set of GLP1-ELP fusions with constant Tt at the injected concentration, but varied MW was characterized and tested in vivo.

Figure 2

Optical density was monitored during heating (solid) and cooling (dashed) to demonstrate reversible phase behavior (data shown for constructs at 100 µM, n=1) (a) and to confirm that the Tt for all constructs remains constant at the injected concentration, indicated by the black dotted circle (b). Activity was assayed in vitro by measuring cAMP response (n=3) after receptor stimulation with fusions or native GLP1 control (c). Blood glucose (d) and percentage weight change relative to weight at t=0 (e) were monitored after treating 7-week old DIO mice (n=6) with a single, SC injection of GLP1-ELP fusions or PBS control. 144 h AUC (f) was quantified for each subject and normalized to the PBS controls in order to compare glycemic regulation across treatment groups. Symbols * and # indicate groups that are statistically significantly different (p<0.05) from all other groups. Data represent the mean and SEM.